Glooko Buys DIABNEXT to Expand French Diabetes Offering

Glooko has acquired DIABNEXT, a Paris-based firm with a digital health platform to help people with diabetes manage their conditions and connect to healthcare providers.
 
DIABNEXT’s mobile app tracks diabetes data so physicians can work with patients to monitor individual data and provide remote care. The DIABNEXT team has joined Glooko in the company’s Paris office and will offer both companies’ platforms in the French market.
 
“We are very pleased to welcome the DIABNEXT team to Glooko and especially excited to add their well-regarded product to Glooko’s portfolio, along with their expertise in the diabetes community in France,” Russ Johannesson, CEO of Glooko told the press. “The addition of DIABNEXT expands our offerings with a unique platform that can help us better customize the patient experience and improve health outcomes for people with diabetes. Glooko’s acquisition of DIABNEXT further cements our commitment to increase our global presence and continue to drive innovative solutions.”
 
Former DIABNEXT CEO Laurent Nicolas is the managing director at the Paris location and will lead efforts in France.
 
“The DIABNEXT team is excited to be part of Glooko. We appreciate the value Glooko places on the product solutions developed for the unique needs of the French market,” said Nicolas. “Not only will this allow us to continue to serve the diabetes community, but with Glooko’s resources and capabilities in device integration, we can now offer more tools to help healthcare professionals provide better care across diabetes-related chronic conditions for the patients they serve.”
 
All existing customers using the DIABENXT platform will continue to be supported. Glooko is working to adopt the French Ministry of Health’s ETAPES program, which supports innovative digital health solutions.
 
“DIABNEXT makes a unique and essential contribution to the management of diabetes,” stated Professor Charles Thivolet, Diabetologist, director and co-founder of DIABe-CARE center. “With its remote monitoring solution already in place at the Hospices Civils de Lyon, DIABNEXT allows us to improve the healthcare pathway for our patients as well as personalize patient follow-up. Together with DIABe-CARE, Diabnext is at the forefront of remote patient monitoring in France, supporting the French initiative to provide innovative technologies in the health sector.”
 
DIABNEXT’s platform will be marketed as Glooko XT.